VDJ-001

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameVDJ-001
Drug Alias NameRecombinant humanized anti-IL-6R monoclonal antibody (Beijing VDJBio)重组人源化抗白介素-6受体单克隆抗体注射液重组人源化抗白介素-6受体单克隆抗体（北京伟德杰生物科技）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsMulticentric Castleman's Disease (MCD)Castleman DiseaseCardiovascular Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Vdjbio Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Vdjbio Co Ltd
Inactive CompaniesN/A
Active IndicationsMulticentric Castleman's Disease (MCD)Castleman DiseaseCardiovascular Diseases +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A